BridgeMD
New treatment option for Periodontitis
Official title Treatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts
ClinicalTrials.gov ID: NCT07146776
What this study is testing
- What it's testing
- The use of injectable platelet-rich fibrin (i-PRF) in both surgical and non-surgical dental treatments has become increasingly widespread. Hard tissue grafts can produce "sticky bone," and bone gain can have a positive effect on intrabony defects frequently seen in periodontal disease, compared to grafts alone.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65. Healthy volunteers may be eligible.
You may be able to join if
- Male and female patients aged 18-65 years
- Patients with Stage III Periodontitis according to the AAP-EFP 2017 Periodontal Disease Classification
- PPD≥5 mm (if persistent 6 weeks after initial periodontal treatment)
- Intrabony defects in the interproximal region with 2 or 3 walls and a depth of at least ≥3 mm
- Non-smokers (those who smoke up to 10 per day may be included)
You likely can't join if
- Patients under 18 years of age or older than 65 years of age
- Patients unable to consent
- Systemic diseases that could affect the success of surgery, such as uncontrolled diabetes
- Single-walled intrabony defects
- Those who have taken antibiotics, anti-inflammatory or immunosuppressive drugs, or birth control pills within the three months prior to the study
- Those who have received active periodontal treatment within the last six months and periodontal surgery within the last year
See the full eligibility criteria
- Male and female patients aged 18-65 years
- Patients with Stage III Periodontitis according to the AAP-EFP 2017 Periodontal Disease Classification
- PPD≥5 mm (if persistent 6 weeks after initial periodontal treatment)
- Intrabony defects in the interproximal region with 2 or 3 walls and a depth of at least ≥3 mm
- Non-smokers (those who smoke up to 10 per day may be included)
- Patients under 18 years of age or older than 65 years of age
- Patients unable to consent
- Systemic diseases that could affect the success of surgery, such as uncontrolled diabetes
- Single-walled intrabony defects
- Those who have taken antibiotics, anti-inflammatory or immunosuppressive drugs, or birth control pills within the three months prior to the study
- Those who have received active periodontal treatment within the last six months and periodontal surgery within the last year
- Smoking more than 10 cigarettes per day
- Pregnancy or breastfeeding
- Those taking medications that affect the gums (e.g., calcium channel blockers, phenytoin or cyclosporine)
- Teeth with furcation defects
- Those undergoing active orthodontic treatment
- Those who are allergic to the biomaterials used in the study or prescribed medications
The study team makes the final eligibility decision.
Where it's taking place
- Istanbul, Üsküdar, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Istanbul, Üsküdar, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.